Quotes 5-day view Delayed London Stock Exchange
06/24/2022
06/27/2022
06/28/2022
06/29/2022
06/30/2022
Date
1637(c)
1666(c)
1685.5(c)
1645.5(c)
1617.5
Last
1 110 588
462 703
721 395
711 842
536 742
Volume
+5.78%
+1.77%
+1.17%
-2.37%
-1.70%
Change
Estimated financial data (e) (USD)
Sales 2022
2 630 M
-
-
Net income 2022
401 M
-
-
Net Debt 2022
545 M
-
-
P/E ratio 2022
11,3x
Yield 2022
2,80%
Sales 2023
2 860 M
-
-
Net income 2023
436 M
-
-
Net Debt 2023
360 M
-
-
P/E ratio 2023
10,4x
Yield 2023
3,12%
Capitalization
4 326 M
4 326 M
-
EV / Sales 2022
1,85x
EV / Sales 2023
1,64x
Nbr of Employees
8 700
Free-Float
66,3%
Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows:
- generic injectable products (41.3%);
- generic products taken orally (32.1%);
- brand name drugs (26.2%);
- other (0.4%).
Net sales are distributed geographically as follows: the United Kingdom...
Ratings of Hikma Pharmaceuticals PLC
All news about HIKMA PHARMACEUTICALS PLC
News in other languages on HIKMA PHARMACEUTICALS PLC
Analyst Recommendations on HIKMA PHARMACEUTICALS PLC
U.S. FTC approves Hikma deal for Custopharm with conditions
Chart HIKMA PHARMACEUTICALS PLC
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends HIKMA PHARMACEUTICALS PLC
Short Term Mid-Term Long Term Trends Neutral Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
10
Last Close Price
19,65 $
Average target price
31,05 $
Spread / Average Target
58,0%
Please enable JavaScript in your browser's settings to use dynamic charts.